Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the mainstay therapies used to treat BPD; their long-standing stronghold as patient-share leaders contribute to the challenges that branded therapies face entering this crowded therapy market. Nevertheless, current treatments have multiple shortcomings; thus, novel therapies with the potential to capitalize on the remaining opportunities in BPD treatment could drive growth of this market. In addition to newer-to-market antipsychotics (e.g., Alkermes’s Lybalvi, Intra-Cellular Therapies’ Caplyta), a handful of emerging therapies from a variety of drug classes are in late-phase development (e.g., Vanda Pharmaceuticals’ iloperidone, NeuroRx’s NRX-101, Sunovion / Sumitomo Dainippon / Otsuka’s SEP-4199), and still more are in early development (e.g., psychedelics). If successful, they could offer new treatment options for BPD.
Questions answered
Geographies: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this research
Epidemiology: Lifetime prevalence, diagnosed prevalence, and drug-treated prevalence of BPD by country
Forecast: 10-year, annualized, drug-level sales and patient share of key BPD therapies through 2032, segmented by brands / generics
Emerging therapies: Preregistration / Phase 3: 5 drugs; coverage of select early-phase products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.